Technology Upgrade Made to SherpaPak Cardiac Transport System 

Paragonix Technologies is enhancing its flagship SherpaPak Cardiac Transport System by introducing TempLock, a next-generation thermal-control innovation designed to improve temperature stability during transport.

Unveiled at ISHLT 2026 (April 22-25, Toronto), the upgraded SherpaPak System now features TempLock technology, engineered to maintain a consistent temperature within a controlled range of 4° to 8°C for extended periods.¹ This advancement builds upon the foundation of Paragonix’s proprietary temperature maintenance approach, further optimizing preservation conditions during the critical window between procurement and transplantation, according to the company.

As donor heart ischemic times continue to increase across the United States, the shift has necessitated greater temperature stability. TempLock temperature stabilization technology is designed to adapt to changing clinical practices and provide more control to transplant surgeons.

The SherpaPak System has been widely adopted to provide controlled hypothermic preservation that has consistently shown to improve outcomes compared to traditional ice storage.^2-4 A recent study published in the Journal of Heart and Lung Transplantation investigating the use of the SherpaPak marked the first time a preservation device has demonstrated significant improvements in survival following heart transplantation.⁴ With the integration of TempLock technology, Paragonix continues to refine its approach, maintaining a clinically relevant and stable temperature range that reflects real-world transport conditions. 

“The evolution of the SherpaPak System is grounded in what matters most to transplant teams—reliability, consistency, and confidence in preservation conditions,” Paragonix Technologies President Dr. Lisa Anderson stated. “Paragonix is focused on innovation and adapting our products and services to meet changing clinical practice. TempLock represents our continued focus on delivering every possible advantage when it matters most.”

This latest innovation reflects Paragonix’s commitment to advancing organ preservation through a combination of engineering precision, clinical insight, and real-world performance data.

Paragonix Technologies, a Getinge company, is redefining the way donor organs are protected and delivered. Built on the belief that every donated organ deserves the highest level of precision and respect, Paragonix partners with transplant centers and OPOs to improve outcomes through clinically proven preservation technologies and expert, hands-on procurement support. Its nationwide transplant services provide 24/7 access to surgical recovery teams, logistics coordination, and clinical excellence— streamlining the recovery process and expanding access to life-saving organs. Combined with real-time digital monitoring, transparent data sharing, and reportedly the world’s largest preservation-focused clinical registries, Paragonix aims to deliver every possible advantage to healthcare providers and patients.

References
¹ Data on file.
² Shudo, Y. et al. A Paradigm Shift in Heart Preservation: Improved Post-Transplant Outcomes in Recipients of Donor Hearts Preserved with the SherpaPak System. ASAIO 2023
³ D’Alessandro et al., Impact of Controlled Hypothermic Preservation on Outcomes Following Heart Transplantation. J Heart Lung Transplant. 2024
⁴ Silvestry et al., Improved 2-year heart transplant survival with moderate hypothermic donor heart preservation in the GUARDIAN heart registry. J Heart Lung Transplant. 2026